The Role of Plasminogen Activator Inhibitor Type 1 (PAI-1) in Placenta-Mediated Pregnancy Complications: A Systematic Review

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is a main inhibitor of fibrinolysis. The PAI-1 gene (SERPINE1) harbors genetic variants with the potential of modifying plasma levels of PAI-1. A delicate balance exists between the coagulation and fibrinolytic system, and changes in PAI-1 have been suggested to compromise establishment of a successful pregnancy. Therefore, this systematic review investigated the association between genetic variants and/or plasma levels of PAI-1 and placenta-mediated pregnancy complications. An extensive literature search was conducted in PubMed, Embase, and Web of Science on the 29^th of April 2021. All studies underwent quality rating according to The Study Quality Assessment Tools checklist provided by National Heart, Lung and Blood Institute. A total of 71 studies were included, among which 60 studies investigated PAI-1 genotypes and 11 studies measured PAI-1 plasma levels. In 32 out of 59 studies, no association was found between the PAI-1 4G/5G polymorphism (rs1799768) and placenta-mediated pregnancy complications, which was stated as no significant difference in the genotype distribution comparing women with and without placenta-mediated pregnancy complications or no significantly increased odds of placenta-mediated pregnancy complications carrying the 4G/4G or 4G/5G genotype. Eight out of 11 studies reported significantly higher PAI-1 plasma levels in preeclamptic women than in women without preeclampsia. In conclusion, no clear evidence indicates that PAI-1 polymorphisms are associated with placenta-mediated pregnancy complications, and the possible association between high PAI-1 plasma levels and preeclampsia needs further investigations. Thus, investigation of PAI-1 genotypes and PAI-1 plasma levels does not currently seem to have a place in daily clinical practice managing placenta-mediated pregnancy complications.

Keywords

placenta-mediated pregnancy complications - plasminogen activator inhibitor type 1 - low-molecular weight heparin - PAI-1 - pregnancy

Publication History

Article published online:
12 January 2022

• References

• 1 Ye Y, Vattai A, Zhang X. et al. Role of plasminogen activator inhibitor type 1 in pathologies of female reproductive diseases. Int J Mol Sci 2017; 18 (08) E1651
• 2 Pannekoek H, Veerman H, Lambers H. et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986; 5 (10) 2539-2544
• 3 Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327 (24) 1729-1733
• 4 D'Elia AV, Fabbro D, Driul L, Barillari G, Marchesoni D, Damante G. Plasminogen activator inhibitor-1 gene polymorphisms in pre-eclampsia. Semin Thromb Hemost 2011; 37 (02) 97-105
• 5 Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences. J Biol Chem 1988; 263 (19) 9129-9141
• 6 Morange PE, Saut N, Alessi MC. et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007; 27 (10) 2250-2257
• 7 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268 (15) 10739-10745
• 8 Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92 (06) 1851-1855
• 9 Ye S, Green FR, Scarabin PY. et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 1995; 74 (03) 837-841
• 10 Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29 (02) 125-130
• 11 Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997; 73 (01) 31-36
• 12 Kruithof EK, Tran-Thang C, Gudinchet A. et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69 (02) 460-466
• 13 Brenner B, Kupferminc MJ. Inherited thrombophilia and poor pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2003; 17 (03) 427-439
• 14 Rodger MA, Paidas M. Do thrombophilias cause placenta-mediated pregnancy complications?. Semin Thromb Hemost 2007; 33 (06) 597-603
• 15 Kofinas A, Kofinas G, Sutija V. The role of second trimester ultrasound in the diagnosis of placental hypoechoic lesions leading to poor pregnancy outcome. J Matern Fetal Neonatal Med 2007; 20 (12) 859-866
• 16 Proctor LK, Whittle WL, Keating S, Viero S, Kingdom JC. Pathologic basis of echogenic cystic lesions in the human placenta: role of ultrasound-guided wire localization. Placenta 2010; 31 (12) 1111-1115
• 17 Lykke JA, Bare LA, Olsen J. et al. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost 2012; 10 (07) 1320-1325
• 18 Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361 (9361): 901-908
• 19 Rodger MA, Walker MC, Smith GN. et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost 2014; 12 (04) 469-478
• 20 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
• 21 National Heart, Lung and Blood Institute. Study Quality Assessment Tools. Accessed March 15, 2021 at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
• 22 De Maat MP, Jansen MW, Hille ET. et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2004; 2 (09) 1588-1593
• 23 Elmahgoub IR, Afify RA, Abdel Aal AA, El-Sherbiny WS. Prevalence of coagulation factor XIII and plasminogen activator inhibitor-1 gene polymorphisms among Egyptian women suffering from unexplained primary recurrent miscarriage. J Reprod Immunol 2014; 103: 18-22
• 24 Gerhardt A, Goecke TW, Beckmann MW. et al. The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J Thromb Haemost 2005; 3 (04) 686-691
• 25 Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 2001; 97 (01) 44-48
• 26 Infante-Rivard C, Rivard GE, Guiguet M, Gauthier R. Thrombophilic polymorphisms and intrauterine growth restriction. Epidemiology 2005; 16 (03) 281-287
• 27 Jeon YJ, Kim YR, Lee BE. et al. Genetic association of five plasminogen activator inhibitor-1 (PAI-1) polymorphisms and idiopathic recurrent pregnancy loss in Korean women. Thromb Haemost 2013; 110 (04) 742-750
• 28 Krause M, Sonntag B, Klamroth R. et al. Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage. Results of a multicentre case-control study. Thromb Haemost 2005; 93 (05) 867-871
• 29 Magdoud K, Herbepin VG, Touraine R, Almawi WY, Mahjoub T. Plasminogen activator inhibitor 1 4G/5G and -844G/A variants in idiopathic recurrent pregnancy loss. Am J Reprod Immunol 2013; 70 (03) 246-252
• 30 Parveen F, Tuteja M, Agrawal S. Polymorphisms in MTHFR, MTHFD, and PAI-1 and recurrent miscarriage among North Indian women. Arch Gynecol Obstet 2013; 288 (05) 1171-1177
• 31 Perés Wingeyer S, Aranda F, Udry S, Latino J, de Larrañaga G. Inherited thrombophilia and pregnancy loss. Study of an Argentinian cohort. Med Clin (Barc) 2019; 152 (07) 249-254
• 32 Said JM, Tsui R, Borg AJ. et al. The PAI-1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women. J Thromb Haemost 2012; 10 (05) 881-886
• 33 Silver RM, Saade GR, Thorsten V. et al. Factor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase mutations and stillbirth: the Stillbirth Collaborative Research Network. Am J Obstet Gynecol 2016; 215 (04) 468.e1-468.e17
• 34 Cui L, Shu C, Liu Z. et al. Serum protein marker panel for predicting preeclampsia. Pregnancy Hypertens 2018; 14: 279-285
• 35 Elzein HO, Muddathir AR, Rida M, Rayis DA, Elhassan EM, Adam I. Fibrinolysis parameters in Sudanese women with severe preeclampsia. Hypertens Pregnancy 2016; 35 (04) 559-564
• 36 Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisløff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999; 78 (03) 191-197
• 37 Aarabi M, Memariani T, Arefi S. et al. Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion. J Matern Fetal Neonatal Med 2011; 24 (03) 545-548
• 38 Al Sallout RJ, Sharif FA. Polymorphisms in NOS3, ACE and PAI-1 genes and risk of spontaneous recurrent miscarriage in the Gaza Strip. Med Princ Pract 2010; 19 (02) 99-104
• 39 Alptekin H, Alptekin N, Selimoğlu R, Cengiz T, Bariş S. Inherited thrombophilia and thromboprophylaxis: a retrospective analysis of pregnancy outcomes in 106 patients. Clin Exp Obstet Gynecol 2017; 44: 749-754
• 40 Barlik M, Seremak-Mrozikiewicz A, Drews K. et al. Correlation between factor VII and PAI-1 genetic variants and recurrent miscarriage. Ginekol Pol 2016; 87 (07) 504-509
• 41 Barlik M, Wolski H, Drews K, Pieńkowski W, Klejewski A, Seremak-Mrozikiewicz A. The contribution of Hind III C>G PAI-1 gene polymorphism in etiology of recurrent miscarriages. Ginekol Pol 2015; 86 (04) 274-279
• 42 Bertinato JF, Morelli VM, Wataru GG. et al. Polymorphisms in thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor type 1 in women with primary recurrent pregnancy loss. Blood 2013; 122 (21) 4795
• 43 Bubalo P, Buterin I, Šalek Z, Ðogić V, Zupančić-Šalek S. Association of plasminogen activator inhibitor-1 gene polymorphisms and methylene tetrahydrofolate reductase polymorphisms with spontaneous miscarriages. Acta Haematol 2017; 138 (02) 111-115
• 44 Buchholz T, Lohse P, Rogenhofer N, Kosian E, Pihusch R, Thaler CJ. Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod 2003; 18 (11) 2473-2477
• 45 Dalmáz CA, Santos KG, Botton MR, Tedoldi CL, Roisenberg I. Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population. Blood Cells Mol Dis 2006; 37 (02) 107-110
• 46 Djurovic J, Stojkovic O, Todorovic J. et al. Genetics of suspected thrombophilia in Serbian females with infertility, including three cases, homozygous for FII 20210A or FV 1691A mutations. Hum Fertil (Camb) 2017; 20 (02) 132-139
• 47 Fabbro D, D'Elia AV, Spizzo R. et al. Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest 2003; 56 (01) 17-22
• 48 Salazar Garcia MD, Sung N, Mullenix TM. et al. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with reproductive failure: metabolic, hormonal, and immune profiles. Am J Reprod Immunol 2016; 76 (01) 70-81
• 49 Häkli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S. Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia. Genet Test 2003; 7 (03) 265-268
• 50 Idali F, Zareii S, Mohammad-Zadeh A. et al. Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase gene mutations in Iranian women with polycystic ovary syndrome. Am J Reprod Immunol 2012; 68 (05) 400-407
• 51 Jeddi-Tehrani M, Torabi R, Zarnani AH. et al. Analysis of plasminogen activator inhibitor-1, integrin beta3, beta fibrinogen, and methylenetetrahydrofolate reductase polymorphisms in Iranian women with recurrent pregnancy loss. Am J Reprod Immunol 2011; 66 (02) 149-156
• 52 Joksic I, Mikovic Z, Filimonovic D. et al. Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in Serbian population. J Med Biochem 2020; 39 (02) 199-207
• 53 Jusić A, Balić D, Avdić A, Pođanin M, Balić A. The association of factor V G1961A (factor V Leiden), prothrombin G20210A, MTHFR C677T and PAI-1 4G/5G polymorphisms with recurrent pregnancy loss in Bosnian women. Med Glas (Zenica) 2018; 15 (02) 158-163
• 54 Kamal M, El-Khayat W. Do serum angiopoietin-1, angiopoietin-2, and their receptor Tie-2 and 4G/5G variant of PAI-1 gene have a role in the pathogenesis of preeclampsia?. J Investig Med 2011; 59 (07) 1147-1150
• 55 Khosravi F, Zarei S, Ahmadvand N. et al. Association between plasminogen activator inhibitor 1 gene mutation and different subgroups of recurrent miscarriage and implantation failure. J Assist Reprod Genet 2014; 31 (01) 121-124
• 56 Kim JJ, Choi YM, Lee SK. et al. The PAI-1 4G/5G and ACE I/D polymorphisms and risk of recurrent pregnancy loss: a case-control study. Am J Reprod Immunol 2014; 72 (06) 571-576
• 57 Kurzawińska G, Barlik M, Drews K. et al. Coexistence of ACE (I/D) and PAI-1 (4G/5G) gene variants in recurrent miscarriage in Polish population. Ginekol Pol 2016; 87 (04) 271-276
• 58 Lino FL, Traina É, Barreto JA, Moron AF, Mattar R. Thrombophilic mutations and polymorphisms, alone or in combination, and recurrent spontaneous abortion. Clin Appl Thromb Hemost 2015; 21 (04) 365-372
• 59 Ozdemir O, Yenicesu GI, Silan F. et al. Recurrent pregnancy loss and its relation to combined parental thrombophilic gene mutations. Genet Test Mol Biomarkers 2012; 16 (04) 279-286
• 60 Patil R, Ghosh K, Vora S, Shetty S. Inherited and acquired thrombophilia in Indian women experiencing unexplained recurrent pregnancy loss. Blood Cells Mol Dis 2015; 55 (03) 200-205
• 61 Pegoraro RJ, Hira B, Rom L, Moodley J. Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in Black South Africans with pre-eclampsia. Acta Obstet Gynecol Scand 2003; 82 (04) 313-317
• 62 Pietropolli A, Giuliani E, Bruno V, Patrizi L, Piccione E, Ticconi C. Plasminogen activator inhibitor-1, factor V, factor II and methylenetetrahydrofolate reductase polymorphisms in women with recurrent miscarriage. J Obstet Gynaecol 2014; 34 (03) 229-234
• 63 Sun L, Lv H, Wei W, Zhang D, Guan Y. Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. J Endocrinol Invest 2010; 33 (02) 77-82
• 64 Torabi R, Zarei S, Zeraati H. et al. Combination of thrombophilic gene polymorphisms as a cause of increased the risk of recurrent pregnancy loss. J Reprod Infertil 2012; 13 (02) 89-94
• 65 Trifonova EA, Swarovskaya MG, Ganzha OA, Voronkova OV, Gabidulina TV, Stepanov VA. The interaction effect of angiogenesis and endothelial dysfunction-related gene variants increases the susceptibility of recurrent pregnancy loss. J Assist Reprod Genet 2019; 36 (04) 717-726
• 66 Vora S, Shetty S, Salvi V, Satoskar P, Ghosh K. Thrombophilia and unexplained pregnancy loss in Indian patients. Natl Med J India 2008; 21 (03) 116-119
• 67 Yamada N, Arinami T, Yamakawa-Kobayashi K. et al. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet 2000; 45 (03) 138-141
• 68 Yenicesu GI, Cetin M, Ozdemir O. et al. A prospective case-control study analyzes 12 thrombophilic gene mutations in Turkish couples with recurrent pregnancy loss. Am J Reprod Immunol 2010; 63 (02) 126-136
• 69 Abdel Gader AM, Al-Mishari AA, Awadalla SA, Buyuomi NM, Khashoggi T, Al-Hakeem M. Total and free tissue factor pathway inhibitor in pregnancy hypertension. Int J Gynaecol Obstet 2006; 95 (03) 248-253
• 70 Balcı Ekmekçi Ö, Ekmekçi H, Güngör Z. et al. Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia. Arch Gynecol Obstet 2015; 292 (01) 53-58
• 71 Djurovic S, Clausen T, Wergeland R, Brosstad F, Berg K, Henriksen T. Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia. BJOG 2002; 109 (07) 759-764
• 72 Oladosu-Olayiwola O, Olawumi H, Babatunde A. et al. Fibrinolytic proteins of normal pregnancy and pre-eclamptic patients in North West Nigeria. Afr Health Sci 2018; 18 (03) 576-583
• 73 Schjetlein R, Haugen G, Wisløff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997; 76 (06) 541-546
• 74 Swellam M, Samy N, Wahab SA, Ibrahim MS. Emerging role of endothelial and inflammatory markers in preeclampsia. Dis Markers 2009; 26 (03) 127-133
• 75 Tobinaga CM, Torloni MR, Gueuvoghlanian-Silva BY. et al. Angiogenic factors and uterine Doppler velocimetry in early- and late-onset preeclampsia. Acta Obstet Gynecol Scand 2014; 93 (05) 469-476
• 76 Bigdeli R, Younesi MR, Panahnejad E. et al. Association between thrombophilia gene polymorphisms and recurrent pregnancy loss risk in the Iranian population. Syst Biol Reprod Med 2018; 64 (04) 274-282
• 77 Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006; 55 (05) 360-368
• 78 Coulam CB, Wallis D, Weinstein J, DasGupta DS, Jeyendran RS. Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis. Am J Reprod Immunol 2008; 60 (05) 426-431
• 79 Cozaru GC, Aschie M, Mitroi A, Brinzan C, Chisoi A. The genetic profile of thrombophilia in reproductive disorders. Revista De Chimie 2019; 70: 3830-3834
• 80 Dordevic V, Gvozdenov M, Pruner I. et al. The prevalence of PAI-1 4G/5G polymorphism in women with fetal loss - first data for a Serbian population. J Med Biochem 2014; 33: 203-207
• 81 Emir M, Skonieczna-Żydecka K, Valijevac A. et al. Lack of association between I/D ACE and-675 ID 4G / 5G PAI-1 polymorphisms and predicting risk of pregnancy loss (PROPALO) in Bosnian women. Proceedings of the International Conference on Medical and Biological Engineering 2017; 62: 440-444
• 82 Ghosh K, Shetty S, Vora S. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in women with fetal loss. Int J Gynaecol Obstet 2009; 107 (02) 159-160
• 83 Goodman C, Hur J, Goodman CS, Jeyendran RS, Coulam C. Are polymorphisms in the ACE and PAI-1 genes associated with recurrent spontaneous miscarriages?. Am J Reprod Immunol 2009; 62 (06) 365-370
• 84 Hefler L, Jirecek S, Heim K. et al. Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. J Soc Gynecol Investig 2004; 11 (01) 42-44
• 85 Lenz B, Samardzija M, Drenjancevic D, Zibar D, Samardzija M, Milostic-Srb A. The investigation of hereditary and acquired thrombophilia risk factors in the development of complications in pregnancy in Croatian women. J Matern Fetal Neonatal Med 2016; 29 (02) 264-269
• 86 Loskutova TO, Demchenko TV, Kryachkova NV. Gene polymorphism of blood coagulation factors and endothelial dysfunction in early and late preeclampsia. Medical Perspectives-Medicni Perspektivi 2020; 25: 66
• 87 Morrison ER, Miedzybrodzka ZH, Campbell DM. et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87 (05) 779-785
• 88 Poursadegh Zonouzi A, Chaparzadeh N, Ghorbian S. et al. The association between thrombophilic gene mutations and recurrent pregnancy loss. J Assist Reprod Genet 2013; 30 (10) 1353-1359
• 89 Shakarami F, Akbari MT, Zare Karizi S. Association of plasminogen activator inhibitor-1 and angiotensin converting enzyme polymorphisms with recurrent pregnancy loss in Iranian women. Iran J Reprod Med 2015; 13 (10) 627-632
• 90 Subrt I, Ulcova-Gallova Z, Cerna M. et al. Recurrent pregnancy loss, plasminogen activator inhibitor-1 (-675) 4G/5G polymorphism and antiphospholipid antibodies in Czech women. Am J Reprod Immunol 2013; 70 (01) 54-58
• 91 Vora S, Shetty S, Ghosh K. Thrombophilic dimension of recurrent fetal loss in Indian patients. Blood Coagul Fibrinolysis 2008; 19 (06) 581-584
• 92 Polat M, Biberoğlu EH, Güler İ, Biberoğlu ÖK. Coexistence of preeclampsia and inherited thrombophilia in Turkish pregnant women. Turk J Med Sci 2016; 46 (04) 1094-1100
• 93 Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91 (05) 861-872
• 94 Kruithof EK, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988; 59 (01) 7-12
• 95 Margaglione M, Cappucci G, d'Addedda M. et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18 (04) 562-567
• 96 Zhao L, Bracken MB, Dewan AT, Chen S. Association between the SERPINE1 (PAI-1) 4G/5G insertion/deletion promoter polymorphism (rs1799889) and pre-eclampsia: a systematic review and meta-analysis. Mol Hum Reprod 2013; 19 (03) 136-143
• 97 Li X, Liu Y, Zhang R, Tan J, Chen L, Liu Y. Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss. Med Sci Monit 2015; 21: 1051-1056
• 98 Huang Z, Tang W, Liang Z. et al. Plasminogen Activator Inhibitor-1 Polymorphism Confers a Genetic Contribution to the Risk of Recurrent Spontaneous Abortion: An Updated Meta-Analysis. Reprod Sci 2017; 24 (11) 1551-1560
• 99 Chen H, Nie S, Lu M. Association between plasminogen activator inhibitor-1 gene polymorphisms and recurrent pregnancy loss: a systematic review and meta-analysis. Am J Reprod Immunol 2015; 73 (04) 292-300
• 100 Su MT, Lin SH, Chen YC, Kuo PL. Genetic association studies of ACE and PAI-1 genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Thromb Haemost 2013; 109 (01) 8-15
• 101 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 197: inherited thrombophilias in pregnancy. Obstet Gynecol 2018; 132 (01) e18-e34
• 102 Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 17: The Investigation and Treatment of Couples with Recurrent First- trimester and Second-trimester Miscarriage. Accessed April 1, 2021 at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf 2011
• 103 Aracic N, Roje D, Jakus IA, Bakotin M, Stefanovic V. The impact of inherited thrombophilia types and low molecular weight heparin treatment on pregnancy complications in women with previous adverse outcome. Yonsei Med J 2016; 57 (05) 1230-1235
• 104 Estellés A, Gilabert J, Keeton M. et al. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84 (01) 143-150
• 105 Guller S, Ma Y, Malek A, Di Santo S, Schneider H. Differential release of plasminogen activator inhibitors (PAIs) during dual perfusion of human placenta: implications in preeclampsia. Placenta 2007; 28 (04) 278-285
• 106 Cruz-Lemini M, Vázquez JC, Ullmo J, Llurba E. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis. Am J Obstet Gynecol 2021; S0002-9378 (20)31288-6
• 107 Sillen M, Declerck PJ. Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition. Front Cardiovasc Med 2020; 7: 622473